The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The prognostic significance of MGUS-like profiles in transplant-eligible patients with myeloma
Borja Puertas, MD, University Hospital of Salamanca, Salamanca, Spain, discusses work investigating the clinical-biological characteristics and prognostic significance of monoclonal gammopathy of unknown significance (MGUS)-like profiles in transplant-eligible patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (autoSCT). Out of over 400 patients studied, MGUS-like profiles were identified in around 10% of individuals and were associated with more indolent disease, superior response rates, and prolonged progression-free survival (PFS) compared to other immunophenotypic groups. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
